
Ivantis said it raised a $27 million Series B round led by Ascension Health Ventures aimed at funding a quartet of clinical trials for its Hydrus Microstent glaucoma treatment.
The Irvine, Calif.-based medical device company said the device, an eyelash-sized stent, is designed to reduce eye pressure.